COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00504270
Recruitment Status : Completed
First Posted : July 19, 2007
Last Update Posted : November 2, 2016
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This study will investigate the safety, efficacy and pharmacokinetics of R3421 in patients with moderate to severe chronic plaque psoriasis. Patients will be randomized to one of 3 treatment groups to receive once daily oral treatment with a)R3421 20mg, b)R3421 120mg, or c)placebo. The anticipated time on study treatment is <3 months, and the target sample size is <100 individuals.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: Placebo Drug: RG3421 120mg Drug: RG3421 20mg Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Study Start Date : July 2007
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Placebo Comparator: Placebo
po daily
Drug: Placebo
po daily

Experimental: RG3421 120mg
120mg po daily
Drug: RG3421 120mg
120mg po daily

Experimental: RG3421 20mg
20mg po daily
Drug: RG3421 20mg
20mg po daily

Primary Outcome Measures :
  1. Adverse events (AEs), laboratory parameters, pharmacokinetics [ Time Frame: Throughout study ]

Secondary Outcome Measures :
  1. Change from baseline in static physician global assessment (PGA) score, Psoriasis Area and Severity Index (PASI) and exploratory biomarkers [ Time Frame: Throughout study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients, 18-70 years of age;
  • medically stable, moderate to severe chronic plaque psoriasis.

Exclusion Criteria:

  • any skin condition which may interfere with evaluation of the effect of study medication on plaque lesions;
  • confounding or concomitant condition or treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00504270

Layout table for location information
United States, Arkansas
Hot Springs, Arkansas, United States, 71913
Little Rock, Arkansas, United States, 72205
United States, California
Santa Monica, California, United States, 90404
United States, Georgia
Alpharetta, Georgia, United States, 30005
United States, New Jersey
East Windsor, New Jersey, United States, 08520
United States, New Mexico
Albuquerque, New Mexico, United States, 87106
United States, New York
New York, New York, United States, 10016
New York, New York, United States, 10029
Stony Brook, New York, United States, 11790
United States, North Carolina
Winston-Salem, North Carolina, United States, 27157
United States, Rhode Island
Providence, Rhode Island, United States, 02903
United States, Tennessee
Nashville, Tennessee, United States, 37215
United States, Texas
Galveston, Texas, United States, 77550
San Antonio, Texas, United States, 78229
Webster, Texas, United States, 77598
Sponsors and Collaborators
Hoffmann-La Roche
Layout table for investigator information
Study Chair: Clinical Trials Hoffmann-La Roche
Layout table for additonal information
Responsible Party: Hoffmann-La Roche Identifier: NCT00504270    
Other Study ID Numbers: NS20454
First Posted: July 19, 2007    Key Record Dates
Last Update Posted: November 2, 2016
Last Verified: November 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases